Discover a new way to find and share stories you'll love… Learn about Reading Desk

Blog Profile / In the Pipeline


URL :http://pipeline.corante.com/
Filed Under:Medical / Pharmaceutical
Posts on Regator:1796
Posts / Week:9.3
Archived Since:November 3, 2010

Blog Post Archive

The Broad Gets $650 Million For Psychiatric Research

The Broad Institute seems to have gone through a bit of rough funding patch some months ago, but things are looking up: they've received a gift of $650 million to do basic research in psychiatric disorders. Believe it, that'll keep everyone...Show More Summary

Put Them in Cells and Find Out

So, when you put some diverse small molecules into cellular assays, how many proteins are they really hitting? You may know a primary target or two that they're likely to interact with, or (if you're doing phenotypic screening), you may not have any idea at all. Show More Summary

The Hep C Field Gets Nastier By the Minute

What a mess there is in the hepatitis C world. Gilead is, famously, dominating the market with Sovaldi, whose price has set off all sorts of cost/benefit debates. The companies competing with them are scrambling to claim positions, and the Wall Street Journal says that AbbVie is really pulling out all the stops. Show More Summary

Allergan Twists and Turns

It's getting nasty over at Allergan. They're still trying to fight off a takeover attempt by Valeant, making the case that the company's R&D efforts are not a waste of money (which, only slightly simplified, is the Valeant position regarding...Show More Summary

Chemistry Class For the "Food Babe"?

I found this article from the Charlotte Observer on the "Food Babe" (Vani Hari) very interesting. A "menu consultant" for Chick-Fil-A, is she? Who knew? I've come across a horribly long string of chemistry misapprehensions, mistakes,...Show More Summary

Thalidomide, Bound to Its Target

There's a new report in the literature on the mechanism of thalidomide, so I thought I'd spend some time talking about the compound. Just mentioning the name to anyone familiar with its history is enough to bring on a shiver. The compound,...Show More Summary

TDP-43 and Alzheimer's

There are quite a few headlines today about a link between Alzheimer's and a protein called TDP-43. This is interesting stuff, but like everything else in the neurodegeneration field, it's going to be tough to unravel what's going on. Show More Summary

Reversal of Type II Diabetes May Be Possible

Here's some big news: Ron Evans and co-workers at Salk report that treatment with the growth factor FGF1 appears to reverse type II diabetes in mice. (Article in Science Daily on this study here). Evans has been working in this field...Show More Summary

An Easy Way to Make Cyclic Peptides

If you ever find yourself needing to make large cyclic peptides, you now have a new option. This paper in Organic Letters describes a particularly clean way to do it: let glutathione-S-transferase (GST) do the work for you. Bradley Pentelute's...Show More Summary

What Structures Have Turned on You?

When you ask a bunch of medicinal chemists to look over a list of structures - screening hits, potential additions to the compound collection, that sort of thing - you'll find that everyone will cross some of them off. But the agreement between the chemists on which ones need to go, that's the tough part. Show More Summary

K. C. Nicolaou on Drug Discovery

K. C. Nicolaou has an article in the latest Angewandte Chemie on the future of drug discovery, which may seem a bit surprising, considering that he's usually thought of as Mister Total Synthesis, rather than Mister Drug Development Project. Show More Summary

The Prospects of an Academic Job

Over the years, there have been more comments than anyone can count here on the often-grim employment picture for chemistry and biology employment in biopharma. Plenty of people here (myself included) can speak from experience. But we should also remember that the academic job market in the biomedical sciences is in awful shape, too, unfortunately. Show More Summary

Targacept Fumbles the Bad News on Alzheimer's

Targacept has been working on some very hard therapeutic areas over the years, and coming up dry - dramatically so. They may have just done it again. They've been testing TC-1734 in Alzheimer's over the last year or so, a partial agonist at nicotinergic receptors. Show More Summary

Modifying Red Blood Cells As Carriers

What's the best carrier to take some sort of therapeutic agent into the bloodstream? That's often a tricky question to work out in animal models or in the clinic - there are a lot of possibilities. But what about using red blood cells...Show More Summary

How to Run a Drug Project: Are There Any Rules at All?

Here's an article from David Shayvitz at Forbes whose title says it all: "Should a Drug Discovery Team Ever Throw in the Towel?" The easy answer to that is "Sure". The hard part, naturally, is figuring out when. You don’t have to beShow More Summary

Employment Among New Chemistry PhDs

Another dose of reality for the "Terrible STEM Shortage!" folks, courtesy of Slate. Here's what author Jordan Weissmann has to say: With a little cleaning up, however, the federal data do tell a pretty clear story: The market for new Ph.D.s in the much obsessed-about STEM fields—science, technology, engineering, and math—is stagnant. Show More Summary

My Imaginary Friends Would Be Glad to Serve as Referees

Here's the biggest fake-peer-review operation I've heard of yet. Retraction Watch, which does not seem to be in any danger of running out of material, reports that a researcher in Taiwan decided to not leave the review process at the Journal of Vibration and Control up to chance. Show More Summary

Biopharma Stock Events for the Rest of the Year

We've had some big biopharma market events so far this year, but if you're wondering what's coming in the next few months, here's a handy rundown from Adam Feuerstein of what may be the top 14. There are a few regulatory events on there, but most of the list are highly anticipated clinical trial results, which is where the action is, for sure. Show More Summary

A Drug Candidate from NCATS

I've written several times about the NIH's NCATS program, their foray into "translational medicine". Now comes this press release that the first compound from this effort has been picked up for development by a biopharma company. The company is AesRx (recently acquired by Baxter), and the compound is AES-103. Show More Summary

No Scripps/USC

The proposed Scripps/USC deal is off, according to reporters Gary Robbins and Bradley Fikes at the San Diego Union-Tribune. No details on what comes next, though - but something presumably does come next.

Copyright © 2011 Regator, LLC